On September 6, 2022 Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, reported that the company and its collaborators will present 14 abstracts at the 2022 European Society for Medical Oncology Congress being held virtually and in person in Paris from September 9-13, 2022 (Press release, Foundation Medicine, SEP 6, 2022, View Source [SID1234619084]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Highlights from the presentations include:
Two studies leveraging Foundation Medicine’s novel homologous recombination deficiency signature (HRDsig) to explore whether this biomarker is associated with FOLFIRINOX benefit in patients with metastatic pancreatic cancer via the Flatiron Health-Foundation Medicine Clinico-Genomic Database (CGDB), and to understand the prevalence of HRDsig positivity in non-small cell lung cancer using FoundationOneCDx.
A real-world analysis of 447 men in the CGDB with de novo metastatic prostate cancer treated in standard of care settings, found that the subgroup with SPOP mutations had much more favorable time to castration resistance and overall survival if treated with second generation hormonal agents versus docetaxel. Another study using Foundation Medicine’s tissue-based comprehensive genomic profiling (CGP) test found that SPOP mutations occur in a moderate number of Clinically Advanced Prostate Cancer (CAPC) cases and are associated with lower frequencies of TMPRSS2: ERG fusions, AR amplifications, cell cycle genomic alterations (GA) and MTOR pathway GA and higher frequencies of immunotherapy drug efficacy biomarkers including microsatellite instability-high (MSI-H), tumor mutational burden high (TMB-H) and PD-L1 status.
A large-scale analysis of lung cancer cases, sequenced using FoundationOne CDx, to identify genomic alterations associated with loco-regional lesions, extracranial metastases and brain metastases to determine their functional roles and downstream pathways, providing a foundation for the development of RICTOR-targeted therapeutic strategies for the treatment and/or prevention of lung cancer brain metastases.
A characterization of the genomic landscapes of TMB-H versus TMB-low (TMB-L) in patients with intrahepatic cholangiocarcinomas (iCCA) using FoundationOne CDx. Findings support the clinical development of immunotherapy approaches for the treatment of TMB-H iCCA patients.
"This data demonstrates the power of our tissue- and liquid-based comprehensive genomic profiling tests for enabling critical research on complex genomic signatures and emerging biomarkers," said Priti Hegde, PhD, Chief Scientific Officer at Foundation Medicine. "We’re proud to be working across the cancer research community to deepen our collective understanding of cancer biology and ultimately support better care for patients in the future."
The following is a list of abstracts that will be presented at the meeting. To access all abstracts being presented at ESMO (Free ESMO Whitepaper), please visit: View Source
Follow Foundation Medicine on Twitter and LinkedIn for more updates from #ESMO22 and visit us in person at booth #306.
Abstract #
Title
Product*
Collaborators
Proffered Paper Session
Sunday, September 11, 2022,
4:40 – 4:50 PM CET
#1696O
Genomic profiling and molecular targeting of lung cancer brain metastases
FoundationOne CDx
Montefiore Einstein Cancer Center
Mini Oral Sessions
Saturday, September 10, 2022,
11:15 – 11:20 AM CET
#660MO
Molecular targets in salivary gland cancers: A comprehensive genomic analysis of 1,666 cases
FoundationOne CDx
Upstate Medical University
Monday, September 12, 2022,
3:35 – 3:40 PM CET
#1487MO
A pan-sarcoma investigation of genetic alterations associated with high telomeric content
FoundationOne Heme
Omico (Australian genomic Cancer Medicine), Garvan Institute of Medical Research; St Vincent’s Clinical School, University of New South Wales, Australia
Posters
Saturday, September 10, 2022
#97P
Pan-cancer landscape of clonal tumor mutational burden (cTMB)
FoundationOne CDx
Massachusetts General Cancer Center, MA, USA; Harvard Medical School, MA, USA; Georgia Institute of Technology, GA, USA; Massachusetts General Hospital, MA, US
Saturday, September 10, 2022
#100P
Co-mutational landscape of key fibroblast growth factor receptor (FGFR) alterations in intra-hepatic cholangiocarcinoma (iCCA), bladder cancer (BC) and glioma
FoundationOne CDx
Ospedale San Raffaele,
Vita-Salute San Raffaele University, Milan, Italy; Tyra Biosciences, Carlsbad, CA, USA; F. Hoffmann-La Roche Ltd, Basel, Switzerland; Jefferson Health, Philadelphia, PA, USA; Ohio State University, Columbus, OH, USA; Repare Therapeutics, Cambridge, MA, USA; Hannover Medical School, Hannover, Germany
Sunday, September 11, 2022
#1373P
SPOP mutations (mtSPOP) are a treatment-selection biomarker in patients (pts) with de novo metastatic castration-sensitive prostate cancer (dn-mCSPC).
Clinico-Genomic Database (CGDB)
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah; University of Minnesota Masonic Cancer Center, Minneapolis, MN
Sunday, September 11, 2022
#1393P
Comparison of genomic alterations (GA) landscape in SPOP mutated (SPOPmut) and SPOP wild type (SPOPwt) clinically advanced prostate cancer (CAPC)
FoundationOne CDx
Ospedale San Raffaele,
Vita-Salute San Raffaele University, Milan, Italy/Moffitt Cancer Center/SUNY Upstate Medical University
Sunday, September 11, 2022
#1368P
TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm)—Exploration of tumor genetics associated with prolonged benefit
FoundationOne CDx
The Institute of Cancer Research and The Royal Marsden Hospital, London, UK; various other institutions; Pfizer
Sunday, September 11, 2022
#1521P
Comprehensive genomic profiling (CGP) of epithelioid hemangioendothelioma (EHE) and liver angiosarcomas (LAS)
FoundationOne CDx
Medical College of Wisconsin
Sunday, September 11, 2022
#1710P
Genomic landscape (GL) with potential of methylthioadenosine phosphorylase (MTAP) loss in clinically advanced breast cancer (CABC)
FoundationOne CDx
Upstate Medical University
Monday, September 12, 2022
#1046P
Homologous recombination deficiency (HRD) and genomic associations in non-small cell lung cancer (NSCLC) using a novel HRD signature (HRDsig)
FoundationOne CDx
UC Davis Health
Monday, September 12, 2022
#1300P
Exploration of a novel HRD signature (HRDsig) as a biomarker of first line FOLFIRINOX benefit in metastatic pancreatic cancer
Clinico-Genomic Database (CGDB)
UPMC Hillman Cancer Center, Pittsburgh, PA
Monday, September 12, 2022
#63P
Intrahepatic cholangiocarcinoma (iCCA) genomic findings with high versus low tumor mutational burdens
FoundationOne CDx
University of Texas MD Anderson Cancer Center
Monday, September 12, 2022
#1778P
Comparative genomic alterations (GA) landscape in urothelial carcinoma of the bladder (UCB) in patients of South Asian ancestry (SAS)
FoundationOne CDx
Ospedale San Raffaele,
Vita-Salute San Raffaele University, Milan, Italy; Moffitt Cancer Center
*May include previous versions of Foundation Medicine’s assays